Drug · CHEMBL696
ETHOSUXIMIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ETHOSUXIMIDE. Drugs and targets, record CHEMBL696. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL696
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- CI-366, CN-10,395, CN-10395, Ethosuximidum, Etosuximida, NSC-64013, PM-671, Pyknolepsinum
- ChEMBL
- Open Targets' highest stage
- Approval, for 1 of its 7 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CACNA1G | Voltage-gated T-type calcium channel | Voltage-gated T-type calcium channel blocker | BLOCKER | https://conductscience.org/library/genes/8913 |
| CACNA1H | Voltage-gated T-type calcium channel | Voltage-gated T-type calcium channel blocker | BLOCKER | https://conductscience.org/library/genes/8912 |
| CACNA1I | Voltage-gated T-type calcium channel | Voltage-gated T-type calcium channel blocker | BLOCKER | https://conductscience.org/library/genes/8911 |
Source ChEMBL
Diseases7
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Abdominal pain | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0002027 |
| irritable bowel syndrome | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005052 |
| neuropathic pain | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0005762 |
| childhood absence epilepsy | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0010826 |
| complex regional pain syndrome | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0019369 |
| depressive disorder | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002050 |
| epilepsy | Approval | ATC, DailyMed and TTD | 12 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005027 |
Source Open Targets
Trials11
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00088452 | Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study | Phase 3 | 453 | 2020-10-14 | ethosuximide | Its name | ClinicalTrials.gov |
| NCT01122381 | Comparison of a Drug and Placebo in the Prevention of Migraine Headaches | Phase 1/2 | 5 | 2015-08-19 | ethosuximide | Its name | ClinicalTrials.gov |
| NCT02973542 | Ethosuximide to Treat IBS | Phase 2 | 162 | ethosuximide | Its name | ClinicalTrials.gov | |
| NCT02100046 | Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain. | Phase 2 | 114 | ethosuximide | Its name | ClinicalTrials.gov | |
| NCT03490487 | Electroclinical Effect of Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes | Phase 4 | 100 | ethosuximide | Its name | ClinicalTrials.gov | |
| NCT04431778 | Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain | Phase 2 | 64 | ethosuximide | Its name | ClinicalTrials.gov | |
| NCT04217733 | Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome | Phase 3 | 60 | ethosuximide | Its name | ClinicalTrials.gov | |
| NCT03887624 | Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. | Early phase 1 | 16 | ethosuximide | Its name | ClinicalTrials.gov | |
| NCT01278004 | Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study) | Phase 2 | 15 | ethosuximide | Its name | ClinicalTrials.gov | |
| NCT00689585 | Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) | Phase 2 | 4 | ethosuximide | Its name | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Arm 1- Ethosuximide vs Arm 2- Placebo Comparator: serious adverse events | 0 of 1 | 0 of 1 | 2 | NCT01122381 |
Source Trial comparisons
Papers from its trials8
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Continuous Performance Test | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL696
GET https://conductscience.org/api/drugs/v1/CHEMBL696/targets